Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 219

1.

Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients.

Shima T, Uto H, Ueki K, Kohgo Y, Yasui K, Nakamura N, Nakatou T, Takamura T, Kawata S, Notsumata K, Sakai K, Tateishi R, Okanoue T.

J Gastroenterol. 2018 Jul 13. doi: 10.1007/s00535-018-1494-7. [Epub ahead of print]

PMID:
30006904
2.

Occult Hepatitis B and Other Unexplored Risk Factors for Hepatocellular Carcinoma in Latin America.

Roman S.

Ann Hepatol. 2018 Jun 20;17(4):541-543. doi: 10.5604/01.3001.0012.0914.

3.

Inhibitory effect of fasiglifam on hepatitis B virus infections through suppression of the sodium taurocholate cotransporting polypeptide.

Nio Y, Akahori Y, Okamura H, Watashi K, Wakita T, Hijikata M.

Biochem Biophys Res Commun. 2018 Jun 27;501(3):820-825. doi: 10.1016/j.bbrc.2018.04.199. Epub 2018 May 4.

PMID:
29723527
4.

[Hepatocellular carcinoma: Increase in incidence or future plague?]

Raoul JL, Raimbourg J, Hiret S, Adhoute X, Senellart H.

Bull Cancer. 2018 May;105(5):502-507. doi: 10.1016/j.bulcan.2018.02.003. Epub 2018 Mar 19. Review. French.

PMID:
29567280
5.

Symptom-based network classification identifies distinct clinical subgroups of liver diseases with common molecular pathways.

Shu Z, Liu W, Wu H, Xiao M, Wu D, Cao T, Ren M, Tao J, Zhang C, He T, Li X, Zhang R, Zhou X.

Comput Methods Programs Biomed. 2018 Feb 22. pii: S0169-2607(17)30780-0. doi: 10.1016/j.cmpb.2018.02.014. [Epub ahead of print]

PMID:
29502851
6.

Impact of sustained virologic response on risk of type 2 diabetes among hepatitis C patients in the United States.

Li J, Zhang T, Gordon SC, Rupp LB, Trudeau S, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Schmidt MA, Daida YG, Lu M; CHeCS Investigators.

J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12887. [Epub ahead of print]

PMID:
29478263
7.

Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature.

Fabiani S, Fallahi P, Ferrari SM, Miccoli M, Antonelli A.

Rev Endocr Metab Disord. 2018 Jan 11. doi: 10.1007/s11154-017-9440-1. [Epub ahead of print] Review.

PMID:
29322398
8.

Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.

Jackson S, Lentino J, Kopp J, Murray L, Ellison W, Rhee M, Shockey G, Akella L, Erby K, Heyward WL, Janssen RS; HBV-23 Study Group.

Vaccine. 2018 Jan 29;36(5):668-674. doi: 10.1016/j.vaccine.2017.12.038. Epub 2017 Dec 27.

9.

Mechanism of Hepatitis C Virus-Induced Diabetes Mellitus.

Ashfaq UA, Khalid H.

Crit Rev Eukaryot Gene Expr. 2017;27(4):363-371. doi: 10.1615/CritRevEukaryotGeneExpr.2017020437.

PMID:
29283331
10.

Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes.

Simeone JC, Bae JP, Hoogwerf BJ, Li Q, Haupt A, Ali AK, Boardman MK, Nordstrom BL.

Clin Epidemiol. 2017 Dec 14;9:679-688. doi: 10.2147/CLEP.S144368. eCollection 2017.

11.

Interaction and joint effect of ALT and chronic liver disease on liver cancer in type 2 diabetes patients.

Li TC, Li CI, Liu CS, Lin PH, Lin WY, Lin CH, Yang SY, Chiang JH, Lin CC.

Oncotarget. 2017 Oct 10;8(61):103851-103863. doi: 10.18632/oncotarget.21804. eCollection 2017 Nov 28.

12.

Prevention, Detection, and Management of Diabetes in South Dakota.

Hogue AL, Huntington MK.

S D Med. 2017 Spec;Spec No:47-53.

PMID:
28817863
13.

Anoectochilus roxburghii: A review of its phytochemistry, pharmacology, and clinical applications.

Ye S, Shao Q, Zhang A.

J Ethnopharmacol. 2017 Sep 14;209:184-202. doi: 10.1016/j.jep.2017.07.032. Epub 2017 Jul 26. Review.

PMID:
28755972
14.

Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease.

Younossi Z, Kochems K, de Ridder M, Curran D, Bunge EM, de Moerlooze L.

Hum Vaccin Immunother. 2017 Nov 2;13(11):2695-2706. doi: 10.1080/21645515.2017.1353850. Epub 2017 Jul 25.

15.

HIV and coronary disease - When secondary prevention is insufficient.

Carvalho AS, Osório Valente R, Almeida Morais L, Modas Daniel P, Sá Carvalho R, Ferreira L, Cruz Ferreira R.

Rev Port Cardiol. 2017 Jul - Aug;36(7-8):569.e1-569.e8. doi: 10.1016/j.repc.2016.10.009. Epub 2017 Jul 8. English, Portuguese.

PMID:
28697899
16.
17.

Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis.

Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB.

Abdom Radiol (NY). 2018 Jan;43(1):13-25. doi: 10.1007/s00261-017-1209-1. Review.

PMID:
28647765
18.

Hepatitis C virus induces a prediabetic state by directly impairing hepatic glucose metabolism in mice.

Lerat H, Imache MR, Polyte J, Gaudin A, Mercey M, Donati F, Baudesson C, Higgs MR, Picard A, Magnan C, Foufelle F, Pawlotsky JM.

J Biol Chem. 2017 Aug 4;292(31):12860-12873. doi: 10.1074/jbc.M117.785030. Epub 2017 May 30.

PMID:
28559285
19.

Serum microRNA signatures as "liquid biopsies" for interrogating hepatotoxic mechanisms and liver pathogenesis in human.

Krauskopf J, de Kok TM, Schomaker SJ, Gosink M, Burt DA, Chandler P, Warner RL, Johnson KJ, Caiment F, Kleinjans JC, Aubrecht J.

PLoS One. 2017 May 17;12(5):e0177928. doi: 10.1371/journal.pone.0177928. eCollection 2017.

20.

Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis.

Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J.

BMJ Open. 2017 May 9;7(5):e013739. doi: 10.1136/bmjopen-2016-013739.

Supplemental Content

Loading ...
Support Center